Investigative Protocols
Clinical Conditions
| Abbreviation | IP Title |
| Female 1 | Evaluation of female infertility |
| Female 2 | Evaluation of irregular periods |
| Female 3 | Hormonal changes during menstrual cycle |
| Female 4 | Hormonal changes during menstrual cycle |
| Prl High | Causes of hyperprolactinaemia (prolactin > 700 mIU/L) |
Coagulation Tests
| Abbreviation | IP Title |
| Platelet | Platelet function analysis |
| Thrombosis | Risk factors for venous thromboembolism |
| vWF1 | von Willebrand disease |
Drug Screen Interpretation
| Abbreviation | IP Title |
| Methadone | Evaluation of EDDP (methadone metabolite) results |
| THC | Evaluation of 9-tetrahydrocannabinol (THC) results |
| UDS | Urine drug screening |
| UDS Amph | Evalution of sympathomimetic amine results |
| UDS Benzo | Evaluation of benzodiazepine results |
| UDS Cocaine | Evaluation of cocaine results |
| UDS Opiate | Evaluation of opiate results |
| UDS TLC | Thin layer chromotography |
Endocrine Tests
| Abbreviation | IP Title |
| Cush | Evaluation of Cushing's syndrome - see flowchart |
| TSH High | Evaluation of an elevated serum TSH (> 4.0 mU/L) |
| TSH Low | Evaluation of a subnormal serum TSH (< 0.2 mU/L) |
General Biochemistry
| Abbreviation | IP Title |
| Bicarb Low | Causes of low plasma bicarbonate (bicarbonate < 18) |
| Calcium High 1 | Causes of hypercalcaemia (calcium > 2.6) |
| Calcium High 2 | Evaluation of hypercalcaemia (calcium > 2.6) |
| Calcium Low | Evaluation of hypocalcaemia (calcium < 2.2) |
| CK High | Causes of an elevated CK (M > 200 F > 140) |
| Globulin High | Evaluation of hyperglobulinaemia (globulins > 44) |
| Glucose Low | Evaluation of hyperglycaemia (plasma glucose < 2.8 mmol/L) |
| LDI | Evaluation of Lactate Dehydrogenase Isoenzymes (LDI) |
| MI Change | Cardiac enzyme changes during myocardial infarction |
| Mag Low | Causes of hypomagnesaemia (magnesium < 0.7mmol/L) |
| Phos High | Causes of hyperphosphataemia (phosphate > 1.8) |
| Phos Low | Causes of hypophosphataemia (mild 0.5~0.65 mmol/L; severe < 0.4 mmol/L) |
| Polyuria | Evaluation of polyuria (urine volume > 3L/24hrs) |
| Pot High 1 | Causes of hyperkalaemia (potassium > 5.0) |
| Pot High 2 | Evaluation of hyperkalaemia (potassium > 5.0) |
| Pot Low 1 | Causes of hypokalaemia (potassium < 3.0) |
| Pot Low 2 | Evaluation of hypokalaemia (potassium < 3.0) |
| Sodium Low | Causes of hyponatraemia (sodium < 130) |
| Urate High | Evaluation of hyperuricaemia (M > 0.45 F > 0.40) |
Immunology
| Abbreviation | IP Title |
| Plasma Cell Dys | Evaluation of plasma cell dyscrasias |
| IgM Plasma Cell Dys | Evaluation of IgM plasma cell dyscrasias |
| Coeliac | Coeliac disease investigation |
| IgA Low | Evaluation of selective IgA deficiency |
Liver Function Tests
| Abbreviation | IP Title |
| ALP High 1 | Causes of an Isolated serum Alkaline Phosphatase (ALP) elevation (ALP > 180 IU/L) |
| ALP High 2 | Evaluation of ALP elevation (ALP > 180 IU/L) |
| ALP High 3 | Evaluation of an isolated serum ALP elevation ? growth related (age < 19 yrs) |
| ALP High 4 | Serum ALP elevation ? growth related (age < 19 yrs) - see flowchart |
| ALP High 5 | Marked serum ALP elevation (ALP > 700 IU/L age < 5 yrs) |
| GGT High | Causes of an elevated serum Gamma Glutamyl Transferase (GGT) (GGT > 100 U/L) |
| LD High | Evaluation of an elevated serum Lactate Dehydrogenase (LD) (LD > 300 U/L) |
| LFT 1 | Evaluation of a moderate elevation of aminotransferase levels (AST & ALT) |
| LFT 2 | Predominant hepatocellular pathology (ALT or AST > 150 U/L ALP < 200 U/L) |
| LFT 3 | Evaluation of a LFT pattern not typical of liver disease (elevated LD, AST > ALT) |
| LFT 4 | Causes of an isolated hyperbilirubinaemia (bilirubin > 25 mmol/L) |
| LFT 5 | Evaluation of an isolated hyperbilirubinaemia (bilirubin > 30 mmol/L) |
| LFT 6 | Evaluation of jaundice (ALT < 400 U/L ALP > 350 U/L) |
| LFT 7 | Evaluation of jaundice (ALT > 300 U/L ALP < 350 U/L) |
| LFT 8 | Evaluation of localised cholestasis (ALP > 180 U/L ALT < 150 U/L GGT > 100 U/L bilirubin < 50 umol/L) |
| LFT 9 | Evaluation of mixed hepatocellular and cholestatic disease (ALP > 180 U/L GGT > 65 U/L ALT or AST > 150 U/L) |
Microbiology & Patient Notes
| Abbreviation | IP Title |
| Haematuria | Causes of isolated microscopic haematuria |
| Occult blood | Faecal occult blood |
| What is Barmah Forest virus? | Symptoms, incubation, treatment and prevention of Barmah Forest virus |
| What is blastocystosis? | Symptoms, infection period, diagnosis, treatment and prevention of blastocystosis |
| What is cryptosporidiosis? | Symptoms, infection period, spread of infection and treatment of cryptosporidiosis |
| What is giardiasis? | Symptoms, infection period, spread of infection, diagnosis, treatment and prevention of giardiasis |
| What is listeriosis? | Symptoms, causes, infection period, diagnosis, treatment and prevention of listeriosis |
| What is parvovirus? | Causes, infection period, spread of infection, diagnosis, treatment and prevention of parvovirus |
| What is Ross River virus? | Symptoms, infection period, spread of infection, diagnosis, treatment and prevention of Ross River virus |
Serology
| Abbreviation | IP Title |
| Hep A | Serological events in acute (self-limiting) Hepatitis A infection relative to Alanine Aminotransferase (ALT) peak |
| Hep B 1 | Serological events in acute (self-limiting) Hepatitis B infection relative to ALT peak |
| Hep B 2 | Hepatitis B immune status |
| Pertussis | Treatment of Bordetella pertussis |
Warfarin Management
| Abbreviation | IP Title |
| Warfarin 1 | Range of International Normalised Ratio (INR) recommended for specific applications of warfarin therapy |
| Warfarin 2 | Guidelines to the management of an elevated INR, with or without bleeding |
| Warfarin 3 | Risk factors for bleeding complications of warfarin therapy |